While many countries are racing to beef up their economically important biopharma industries through a variety of support measures, a recent research report suggests that South Korea first needs to establish an appropriate role for the government in line with the development stage of the domestic industry if it is to become a flagship sector.
Compared with the US and Switzerland, whose mature systems have largely focused on improving regulations, systems and corporate incentives to...